Literature DB >> 1450873

HRT and osteoporosis.

J E Compston1.   

Abstract

Osteoporosis is characterised by low bone mass, leading to an increased risk of fragility fracture, particularly in the femoral neck, vertebrae and radius. These fractures constitute a major public health problem in the Western world; the estimated annual cost to the health services of hip fracture alone is over 500 million pounds in the United Kingdom. Using population-based data from the USA, Cummings et al. have estimated that the lifetime risks of hip, vertebral and Colles' fractures in a 50 year old, white, postmenopausal woman are 16%, 32% and 15% respectively. Of these, vertebral fractures probably cause the most significant morbidity, since they occur at a younger age than hip fractures and may result in pain, deformity and disability for many years until death intervenes from other causes. Hip fractures occur most commonly in the eight and ninth decades of life and have a mortality at six months of around 15%, increased dependency occurring in the majority of survivors. Colles' fractures, although not usually associated with long-term morbidity, nevertheless cause considerable inconvenience and require hospital treatment.

Entities:  

Mesh:

Year:  1992        PMID: 1450873     DOI: 10.1093/oxfordjournals.bmb.a072549

Source DB:  PubMed          Journal:  Br Med Bull        ISSN: 0007-1420            Impact factor:   4.291


  11 in total

Review 1.  Postmenopausal hormone replacement therapy.

Authors:  H S Jacobs; F E Loeffler
Journal:  BMJ       Date:  1992-12-05

Review 2.  The menopause and hormone replacement therapy.

Authors:  K T Khaw
Journal:  Postgrad Med J       Date:  1992-08       Impact factor: 2.401

3.  Hormone replacement therapy again. Risk-benefit relation differs between populations and individuals.

Authors:  K T Khaw
Journal:  BMJ       Date:  1998-06-20

4.  Evolution of osteoporosis.

Authors:  D W Purdie
Journal:  Ann Rheum Dis       Date:  1996-06       Impact factor: 19.103

5.  Estrogen protects lenses against cataract induced by transforming growth factor-beta (TGFbeta).

Authors:  A M Hales; C G Chamberlain; C R Murphy; J W McAvoy
Journal:  J Exp Med       Date:  1997-01-20       Impact factor: 14.307

Review 6.  Hormone replacement therapy: II. A pharmacoeconomic appraisal of its role in the prevention of postmenopausal osteoporosis and ischaemic heart disease.

Authors:  R Whittington; D Faulds
Journal:  Pharmacoeconomics       Date:  1994-06       Impact factor: 4.981

Review 7.  The therapeutic use of bisphosphonates.

Authors:  J E Compston
Journal:  BMJ       Date:  1994-09-17

8.  Salmon calcitonin nasal spray : An effective alternative to estrogen therapy in select postmenopausal women.

Authors:  L V Avioli
Journal:  Endocrine       Date:  1996-10       Impact factor: 3.633

9.  Hormonal replacement therapy in menopausal women with a history of hyperprolactinemia.

Authors:  P Touraine; C Deneux; G Plu-Bureau; P Mauvais-Jarvis; F Kuttenn
Journal:  J Endocrinol Invest       Date:  1998-12       Impact factor: 4.256

10.  Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta.

Authors:  B Stein; M X Yang
Journal:  Mol Cell Biol       Date:  1995-09       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.